Karyopharm’s Selinexor: US FDA Unconvinced By Efficacy In Single-Arm Trial

 
• By Michael McCaughan
  
Athletic woman training_1101761456_1200.jpg
Will a single arm be enough for Karyopharm’s proposed refractory myeloma therapy selinexor?
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers